U.S. stock market update: Klotho Neurosciences down 7.50%

U.S. Stock Market Midday Update Klotho fell 7.50%, up 178.45% year-to-date. Based on recent important news: On July 10, Klotho announced that its ALS treatment candidate received FDA orphan drug designation, causing the stock price to rise 3.66%. On June 10, Klotho's research results showed that its therapy is expected to extend healthy lifespan, leading to a 500% surge in stock price. On July 10, the market anticipated that clinical progress could bring volatility, resulting in a 5.8% increase in stock price. Stocks with High Trading Volume in the Industry MiNK Therapeutics rose 624.84%. Based on recent important news: On July 11, MiNK Therapeutics announced that its experimental allogeneic cell therapy agenT-797 showed complete remission in a patient with advanced testicular cancer, driving the stock price up 522%. On July 11, the successful case of this therapy was published in Oncogene, further boosting market confidence. On July 11, the market held an optimistic view on the potential of iNKT cell therapy in treating solid tumors, leading to a significant increase in stock price. AbbVie fell 1.35%, with increased trading volume. Based on recent important news: On July 11, AbbVie signed a licensing agreement with Glenmark, paying $700 million, and the market held an optimistic view on its innovative drug prospects, leading to increased stock price volatility. On July 10, analysts maintained a hold rating on AbbVie but did not include it in their recommended list, affecting investor confidence. On July 9, the innovative drug industry experienced high volatility, with low institutional allocation ratios, leading to sensitive market reactions. Gilead Sciences fell 3.29%, with increased trading volume. Based on recent important news: On July 9, Gilead reached an agreement with the Global Fund to accelerate the provision of HIV prevention drug Lenacapavir in low-income countries, supplying 2 million people at no profit over three years. This move failed to boost market confidence, resulting in a stock price decline. On July 9, analysts noted that Gilead was not included in the top recommended stock list, despite its moderate buy rating, leading to negative market reactions. On July 10, Gilead reached an agreement with Kymera Therapeutics to develop a novel molecular glue degraders, which did not immediately impact the stock price. Stocks with High Market Capitalization in the Industry Amgen fell 1.77%, with increased trading volume. Based on recent important news: On July 11, MarketBeat pointed out that Amgen was not included in the list of top five stocks recommended by analysts, leading to insufficient market confidence and downward pressure on the stock price. On July 10, analysts believed that Amgen's valuation was reasonable, with a forward P/E ratio below the industry average; nevertheless, the market remained cautious about its growth potential On July 9th, Oregon Congressman Cliff Bentz purchased Amgen stock. Although the transaction amount was not large, it failed to boost market sentiment